Recent research with mouse models and ErbB2-positive breast cancer patients has shown that antibiotic administration substantially altered the gut microbiota composition and impaired immune-mediated trastuzumab therapeutic activity, revealing the involvement of the gut microbiota in trastuzumab responsiveness (47). The gene discussed is ERBB2; the disease is breast cancer.